Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Capital Expenditures: 2010-2024

Historic Capital Expenditures for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $1.2 million.

  • Capricor Therapeutics' Capital Expenditures rose 510.64% to $55,843 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 39.76%. This contributed to the annual value of $1.2 million for FY2024, which is 11.04% down from last year.
  • As of FY2024, Capricor Therapeutics' Capital Expenditures stood at $1.2 million, which was down 11.04% from $1.3 million recorded in FY2023.
  • Capricor Therapeutics' Capital Expenditures' 5-year high stood at $2.0 million during FY2022, with a 5-year trough of $547,601 in FY2020.
  • For the 3-year period, Capricor Therapeutics' Capital Expenditures averaged around $1.5 million, with its median value being $1.3 million (2023).
  • In the last 5 years, Capricor Therapeutics' Capital Expenditures soared by 118.46% in 2021 and then plummeted by 34.42% in 2023.
  • Over the past 5 years, Capricor Therapeutics' Capital Expenditures (Yearly) stood at $547,601 in 2020, then surged by 118.46% to $1.2 million in 2021, then soared by 67.20% to $2.0 million in 2022, then plummeted by 34.42% to $1.3 million in 2023, then decreased by 11.04% to $1.2 million in 2024.